JP7725466B2 - バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法 - Google Patents

バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法

Info

Publication number
JP7725466B2
JP7725466B2 JP2022526756A JP2022526756A JP7725466B2 JP 7725466 B2 JP7725466 B2 JP 7725466B2 JP 2022526756 A JP2022526756 A JP 2022526756A JP 2022526756 A JP2022526756 A JP 2022526756A JP 7725466 B2 JP7725466 B2 JP 7725466B2
Authority
JP
Japan
Prior art keywords
polypeptide
xten
sequence
polypeptides
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022526756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501478A (ja
JP2023501478A5 (https=
Inventor
フォルカー・シェレンベルガー
エリック・ジョハンセン
アンゲラ・ヘンケンジーフケン
Original Assignee
アムニクス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムニクス ファーマシューティカルズ， インコーポレイテッド filed Critical アムニクス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023501478A publication Critical patent/JP2023501478A/ja
Publication of JP2023501478A5 publication Critical patent/JP2023501478A5/ja
Priority to JP2025130787A priority Critical patent/JP2025179058A/ja
Application granted granted Critical
Publication of JP7725466B2 publication Critical patent/JP7725466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2022526756A 2019-11-13 2020-11-13 バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法 Active JP7725466B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025130787A JP2025179058A (ja) 2019-11-13 2025-08-05 バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934980P 2019-11-13 2019-11-13
US62/934,980 2019-11-13
PCT/US2020/060378 WO2021097186A1 (en) 2019-11-13 2020-11-13 Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025130787A Division JP2025179058A (ja) 2019-11-13 2025-08-05 バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法

Publications (3)

Publication Number Publication Date
JP2023501478A JP2023501478A (ja) 2023-01-18
JP2023501478A5 JP2023501478A5 (https=) 2023-11-17
JP7725466B2 true JP7725466B2 (ja) 2025-08-19

Family

ID=73740585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022526756A Active JP7725466B2 (ja) 2019-11-13 2020-11-13 バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
JP2025130787A Pending JP2025179058A (ja) 2019-11-13 2025-08-05 バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025130787A Pending JP2025179058A (ja) 2019-11-13 2025-08-05 バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法

Country Status (12)

Country Link
EP (1) EP4058466A1 (https=)
JP (2) JP7725466B2 (https=)
KR (1) KR20220131221A (https=)
CN (1) CN115175920B (https=)
AU (1) AU2020382621A1 (https=)
BR (1) BR112022009217A2 (https=)
CA (1) CA3157605A1 (https=)
CO (1) CO2022008004A2 (https=)
IL (1) IL292863A (https=)
MX (1) MX2022005676A (https=)
PH (1) PH12022551163A1 (https=)
WO (1) WO2021097186A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3143519A1 (en) * 2019-06-26 2020-12-30 Volker Schellenberger Cd3 antigen binding fragments and compositions comprising same
KR20230041711A (ko) * 2020-06-25 2023-03-24 아뮤닉스 파마슈티컬스, 인크. Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법
WO2023092099A1 (en) * 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2025122957A1 (en) 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003536048A (ja) 1999-03-23 2003-12-02 バイオヴェイション リミテッド タンパク質の単離および分析
US20180030531A1 (en) 2016-07-29 2018-02-01 The Regents Of The University Of California Methods for determining gene functions

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3484377D1 (de) 1983-06-15 1991-05-08 Celltech Ltd Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
DK27885A (da) 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
EP0593065B1 (en) 1985-09-12 2002-08-21 Scios Inc. Recombinant fibroblast growth factors
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5631230A (en) 1989-09-21 1997-05-20 Arizona Technology Development Corporation Receptor selective analogues of cholecystokinin-8
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5364840A (en) 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
EP0548267A4 (en) 1990-09-04 1994-11-23 Salk Inst Biotech Ind Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
KR960701653A (ko) 1993-03-29 1996-03-28 발라수브라마니암 엠비카이파칸 펩타이드 yy의 유사체 및 그의 용도
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US6214797B1 (en) 1995-06-13 2001-04-10 The Salk Institute For Biological Studies Urocortin peptides, nucleic acid encoding same methods for using same
DE69602756T2 (de) 1995-08-18 2000-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
ES2401939T3 (es) 1999-07-23 2013-04-25 Kenji Kangawa Nuevos péptidos
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20020119490A1 (en) * 2000-12-26 2002-08-29 Aebersold Ruedi H. Methods for rapid and quantitative proteome analysis
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7419949B2 (en) 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
US6965013B2 (en) 2002-11-26 2005-11-15 The Board Of Trustees Of The Leland Stanford Junior University Intermedin and its uses
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
CN101309703A (zh) 2005-09-12 2008-11-19 诺维莫尼公司 抗cd3抗体组合物
CA2989778C (en) 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
EP2370467B1 (en) 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
AU2015200260A1 (en) * 2009-06-08 2015-02-12 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
KR101813727B1 (ko) 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
MX2017006016A (es) * 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
WO2016145416A2 (en) * 2015-03-11 2016-09-15 The Broad Institute, Inc. Proteomic analysis with nucleic acid identifiers
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure
JP6558679B2 (ja) 2015-04-24 2019-08-14 パナソニックＩｐマネジメント株式会社 点灯装置、照明装置及び照明器具
AU2016253964B2 (en) * 2015-04-27 2022-07-07 Abvitro Llc Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
WO2019074841A1 (en) * 2017-10-09 2019-04-18 Pioneer Hi-Bred International, Inc. TYPE I-E CRISPR-CAS SYSTEMS FOR EUCARYOTE GENOME EDITION
AU2018393111B2 (en) * 2017-12-21 2025-07-10 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003536048A (ja) 1999-03-23 2003-12-02 バイオヴェイション リミテッド タンパク質の単離および分析
US20180030531A1 (en) 2016-07-29 2018-02-01 The Regents Of The University Of California Methods for determining gene functions

Also Published As

Publication number Publication date
JP2025179058A (ja) 2025-12-09
CN115175920B (zh) 2025-10-31
CA3157605A1 (en) 2021-05-20
KR20220131221A (ko) 2022-09-27
WO2021097186A1 (en) 2021-05-20
CN115175920A (zh) 2022-10-11
EP4058466A1 (en) 2022-09-21
US20230287040A1 (en) 2023-09-14
BR112022009217A2 (pt) 2022-08-02
MX2022005676A (es) 2022-10-27
PH12022551163A1 (en) 2023-09-25
JP2023501478A (ja) 2023-01-18
CO2022008004A2 (es) 2022-10-21
IL292863A (en) 2022-07-01
AU2020382621A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
JP7725466B2 (ja) バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
US20230324389A1 (en) Compositions and methods related to activatable therapeutic agents
CN104768571B (zh) 多价异多聚体支架设计和构建体
DK2681245T3 (en) MULTIVALENT HEAT-MULTIMED SCAFFOLD DESIGN AND CONSTRUCTIONS
CN106456733A (zh) Syntac多肽及其用途
CN114127277A (zh) 蛋白酶底物和包含蛋白酶切割序列的多肽
JP2024164077A (ja) 翻訳後修飾が低減したペプチドリンカー
CN120380013A (zh) 掩蔽多肽、可活化的新型前药及其使用方法
US12617815B2 (en) Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same
EP2906237B1 (en) Multivalent heteromultimer scaffold design and constructs
RU2851152C1 (ru) Нацеленные на her-2 биспецифические композиции и способы их получения и применения
TW202321459A (zh) 可活化治療劑相關之組合物及方法
RU2815452C2 (ru) Полипептид, включающий антигенсвязывающий домен и транспортирующий сегмент
HK40064164A (en) Protease substrate, and polypeptide including protease cleavage sequence
HK40044319A (en) Peptidic linker with reduced post-translational modification
HK1212615B (en) Multivalent heteromultimer scaffold design and constructs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241101

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241111

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250806

R150 Certificate of patent or registration of utility model

Ref document number: 7725466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150